| INTRODUCTION
Haemophilia is a group of inherited haemorrhagic disorders caused by defects in, or the absence of, critical factors in the coagulation cascade, which severely compromise thrombin generation and fibrin clot formation. This leads to spontaneous bleeding episodes, most commonly in joints and internal organs, to intracranial bleeds and to excessive bleeding during and following surgery or trauma; frequent bleeding can cause joint swelling, joint damage, severe deformity, frequent infections and reduced mobility in patients with haemophilia. 1 Haemophilia A is caused by defects in or a lack of factor VIII (FVIII) expression, while haemophilia B is caused by defects in or lack of factor IX expression. The prevalence of haemophilia in the United States has been estimated at 1 in 6000 individuals for haemophilia A and 1 in 25 000 individuals for haemophilia B. bypass deficiencies or inhibitors that abrogate the intrinsic coagulation pathway. 3, 4 Previous experience in humans has established recombinant FVIIa (rFVIIa) as an effective emergency treatment for haemophiliacs with inhibitors through frequent administration of the drug to control haemorrhage. 5 Standard regimens for the treatment of spontaneous bleeding include one infusion of 270 μg/kg of rFVIIa or up to three infusions of 90 μg/kg every 3 hours following a bleeding episode due to the drug's short half-life of 2.9 hours. 6, 7 Similar to replacement of FVIII and FIX, the short half-life of rFVIIa decreases the practicality of the drug as a prophylactic agent to reduce the frequency of spontaneous bleeding episodes. Although not an approved indication, the only commercially available rFVIIa product (NovoSeven, Novo Nordisk, Denmark) was shown to be effective as a prophylactic treatment. 8 MOD-5014 is a long-acting rhFVIIa developed for the treatment of haemophilia A or B using either an intravenous (IV) or subcutaneous (SC) injection. MOD-5014 is being developed for on-demand treatment of spontaneous bleedings (eg, joint bleeding) with the aim of less frequent administrations, as well as for prophylactic use with an anticipated dosing regimen of two to three times a week. The prolonged circulation time of MOD-5014 is the result of three consecutive Cterminal peptide (CTP) repeats at the C-terminus of FVII. The CTP technology is based on the C-terminal peptide of the beta chain of human chorionic gonadotropin. 9, 10 This technology has been clinically validated upon the approval of corifollitropin alfa (Elonva, Merck) by the European authorities and is currently utilized to extend the halflife of human growth hormone (MOD-4023), 11 which is in advanced clinical stage in growth hormone-deficient adults and children. 12, 13 Understanding the way that the CTP affects the biological function of MOD-5014 in comparison with rhFVIIa is important to gauge any potential differences in the safety profile of MOD-5014 when compared to rhFVIIa. To this end, this study presents a summary of the comprehensive in vitro characterization undertaken to comparatively evaluate the activity of FVIIa-CTP 3 (MOD-5014) vs rhFVIIa following the attachment of CTP, as well as their interaction with cofactors and inhibitors; this work paves the way for in vivo pharmacology and toxicology evaluations of MOD-5014 in animal models. calculated on the basis of specific absorbance at 280 nm using an empirically determined extinction coefficient of 1.27 mL/mg/cm.
| MATERIALS AND METHODS

| FVIIa-CTP (MOD-5014) and rhFVIIa
| Clotting activity
The in vitro clotting activity of FVIIa was measured using the Staclot 
| Surface plasmon resonance
The interactions between MOD-5014 and rhFVIIa to sTF were studied using ProteOn 36XPR (Bio-Rad, Hercules, CA, USA) at the ProteOn unit, the National Institute for Biotechnology in the Negev 
| Chromogenic substrate assays
The potency of MOD-5014 and rhFVIIa was also assessed using the BIOPHEN FVII chromogenic assay (Hyphen BioMed). All experiments were performed at least 3 times, and error in the fitting parameters was determined by bootstrapping. Factor X is present in 
| Thrombin generation
Thrombin generation (TG) was measured according to Livnat et al. [15] [16] [17] Briefly, pooled plasma from severe FVIII-deficient patients Thrombin generation was detected by colour development at 405 nm.
| Rotation thromboelastometry
Pooled plasma from severe FVIII-deficient patients was spiked with either MOD-5014 or rhFVIIa at concentrations of 0, 2.5, 10 or 15 μg/ 
| RESULTS
| In vitro activity
The specific activities of MOD-5014 and rhFVIIa were evaluated using a Staclot VIIa-rsTF assay. MOD-5014 has 35% of the spe- values of MOD-5014 and rhFVIIa were assessed using a chromogenic assay intended for testing FVII activity by measuring FX activation and were found to be 0.41 and 0.38 ng/mL, respectively.
To compare the PT and aPTT profiles of MOD-5014 and rhFVIIa, the two compounds were spiked in human haemophilia and FVIIdeficient plasma. When MOD-5014 and rhFVIIa were spiked at a similar range of concentrations, PT measurements were comparable for both compounds, and aPTT was slightly longer for MOD-5014 (Table 1) . To compare the effect of the two compounds on TG, severe haemophilia A pooled plasma was spiked with MOD-5014 and rhFVIIa at a wide range of concentrations. A dose-dependent response was observed following the addition of the two compounds ( Figure 1A-D) . When TG was initiated by recalcification only, no TG was detected in the absence of MOD-5014 or rhFVIIa as reflected by the flat curve. As shown in Figure 1A ,B, at low concentrations observed at all MOD-5014 and rhFVIIa concentrations (see Figure   S1 and Figure S2 ). Although the higher concentration provided a pronounced improvement in the TG profile, none of the tested compounds were able to provide a complete restoration of the TG as compared to normal TG obtained with spiking of the FVIII-deficient plasma with 100% FVIII ( Figure 1E ). Finally, the ability of MOD-5014 binding of platelets to support platelet surface thrombin generation was assessed. As shown in Figure 1F , MOD-5014 supported rates of thrombin generation that were slightly lower than rhFVIIa.
The lag prior to the onset of thrombin generation was ~40% longer with MOD-5014 than with rhFVIIa.
The ROTEM performance of both MOD-5014 and rhFVIIa was evaluated in severe haemophilia A plasma at a range of concentra- (Table 2) . 
T A B L E 1 Prothrombin time (PT) and activated partial thromboplastin time (aPTT) measurements of MOD-5014 and rhFVIIa
| Interaction with TF and lipids
| Interaction with TFPI, AT and heparin
A comparison of MOD-5014 and rhFVIIa clotting activity inhibition profiles in the presence of tissue factor pathway inhibitor (TFPI), a natural inhibitor of FVIIa, showed that TFPI inhibited rhFVIIa and MOD-5014 and in a similar dose-dependent manner ( Figure 3A ).
The addition of heparin to either MOD-5014 or rhFVIIa resulted in >96% inhibition for both compounds, even at the extremely low concentration of 0.1 U/μL (results not shown). The clotting activities of MOD-5014 and rhFVIIa were also evaluated in the presence of antithrombin, which resulted in a similar rate of inhibition ( Figure 3B ). maintain proper haemostasis and control bleeding will be evaluated in a clinical setting.
The binding affinity of MOD-5014 to TF was found to be similar to that of rhFVIIa and comparable to previously reported K d values. [18] [19] [20] [21] [22] [23] The interaction of FVIIa and TF mainly takes place at the light-chain region of the coagulation factor, 24 which is distant from the FVII-CTP fusion area (located in the heavy-chain region of FVII).
Therefore, the fused CTP is unlikely to interfere with FVII/TF bind- 
| CONCLUSION
The present work has established the comparable in vitro activity of MOD-5014 and rhFVIIa, thus paving the way for subsequent in vivo pharmacology evaluations of this novel compound in preparation for clinical studies.
